27027

17-AAG

17-AAG binds specifically to heat shock protein Hsp90 in a manner similar to geldanamycin, but the binding is weaker. Inhibits Akt activation and HER2 expression in tumor cells. Exhibits 100-fold higher binding affinity for tumor-cell-derived hsp90 over that derived from normal cells. Inhibits angiogenesis.

435.00 €

1774-5

17-AAG

1208.40 €

1774-50

17-AAG

Ask for quotation

DLL-0011-2ML

Tanespimycin (17-AAG) Liposomes, Formulation XT28.1

PEGylated liposomes containing Hsp90 inhibitor Tanespimycin (17-AAG). Tanespimycin exhibits 100-fold higher binding affinity to HSP90 derived from tumor cells vs normal cells, and induces apoptosis, necrosis, autophagy, and mitophagy. Tanespimycin is insoluble in aqueous media. This product is a pre-formulated liposomal version of Tanespimycin which is supplied ready to use in vitro or in vivo. The liposomes are PEGylated for optimal in vivo performance. For preclinical research use only.

995.00 €

A7088-100

L-NAME hydrochloride

Amino Acids & Building Blocks|Amino Acids and Derivatives#Others|nNOS#Others

335.00 €

A7088-1000

L-NAME hydrochloride

Amino Acids & Building Blocks|Amino Acids and Derivatives#Others|nNOS#Others

317.00 €